TrialThe oncologist2020

A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting.

Pedro Sánchez-Rovira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.